Home › Therapeutic areas › Oncology › Bladder Cancer

Bladder Cancer (11 companies)

Companies with an active program in Bladder Cancer.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
AKTS Aktis Oncology Oncology 1 Phase 1 $910M 10
ARTV Artiva Biotherapeutics Oncology 1 Phase 1 $191M 6
BCYC Bicycle Therapeutics Oncology 2 Phase 2 $224M 4
CGON CG Oncology Oncology 1 NDA Submitted $7.05B 1
EXEL Exelixis CardiovascularOncology 1 Approved $16.7B 23
IBRX ImmunityBio Infectious DiseaseOncology 3 Approved $6.66B 17
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $143M 3
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $321M 4
SMMT Summit Therapeutics Oncology 1 NDA Submitted $8.53B 6
TYRA Tyra Biosciences MetabolicOncology Rare 2 Phase 2 $1.35B 5